Canon Medical Reinforces Commitment to AI Innovation With New Altivity Brand

Canon Medical has today announced the launch of Altivity, a new AI innovation brand, that consolidates machine learning and deep learning technologies to deliver uncompromised quality and value across the entire care pathway.

Canon Medical has been steadily redefining the role of AI in healthcare, starting with its Advanced intelligent Clear-IQ Engine (AiCE). Initially developed for CT, this denoising deep learning technology was soon deployed across MRI and PET/molecular imaging to help speed up scan times and improve image quality. Next came the launch of Automation Platform and AUTOStroke solution, both of which were designed to enhance clinical confidence and streamline workflows with the power of deep learning technology.

More recently, Canon Medical has transformed the ultrasound space with AI innovations*, that revolutionize clinical workflows. One of the most time-consuming aspects of an ultrasound exam is the care that must be taken to ensure serial measurements are done in a standardized and highly reproducible way. By leveraging the power of AI, Canon Medical has been able to automate these routine tasks to increase clinical productivity and reporting accuracy.

Under the promise of Intelligent healthcare made easy, Altivity enables:

  • Informed healthcare
    Altivity is here to help enhance clinical confidence with high-quality images and applications that help make informed decisions in real time.
  • Fast, tailored care
    Altivity has been created with patients in mind, to deliver the fast and accurate results they need for a more personalized treatment approach.
  • Efficient workflows
    Altivity helps create simple, streamlined AI-driven workflows that optimize resource deployment and ensure your teams have the insights they need to work smarter every day.

Toshio Takiguchi, President and CEO of Canon Medical, says of the launch, “We are passionate about the development of intelligent imaging solutions that reflect the changing medical landscape. With Altivity, we are strengthening our focus to help clinicians leverage their data and transform it into essential insight that improves outcomes for everyone.”

Naoki Sasaki, Head of Research and Development, echoed these sentiments by saying that “Canon Medical’s commitment to continued research and development has resulted in products that are establishing new standards in the area of AI in medicine and healthcare.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version